Selinexor Gains FDA Fast Track Designation for Refractory Multiple Myeloma Patients
News
Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received Fast Track designation by the U.S. Food and Drug Administration (FDA), for the treatment of refractory multiple myeloma patients — those ... Read more